Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In response to your implication that Mr Bailey might not have worked for Exxon---a Mother Jones article quotes him on oil politics and states he was there until sometime in 1997. Bloomberg which I presume verifies also lists him as a VP. I don't mind your negative posts because I have similar concerns about the evolving story that seems to now lean to remediation not production. I do mind you trying to misdirect. If I can find that info so can anyone. I'm not that good at internet searches.
I realize they're going to spend money but right now, is the company not at about $6.50/share alone given the recent royalty conversion?
January should be interesting with hoped for announcements.
is it likely licensing and remediation contracts would happen before the plant is up and running? If not it seems like a quiet six months. Doesn't feel like you'd hire a new IR service for a spring launch of a new plant?
Seems like real news next month?
I assume year end numbers around mid-October?
Wall Street Journal spotlight probably will matter.
Any idea if a partner is needed for a vaccine?
Is dilution inevitable?
Seems like other nasal applications possible
Market cap seemingly doesn't reflect growth of actual sales or potential.
Has any analyst suggested the percentage of the market share AYTU could capture with their nasal spray? Liked what I heard on the call. Concerned like always with dilution for a small company but next several months should be positive news. Was it the large company Endo that handled the spray before AYTU? How do you miss on that?
The 13 year effort that went through one hundred million and addresses something Aethlon does not? Please state it can do other things.
Any idea why my post was deleted? Happened before. Curious and apparently intentional. but one can cry "sham" and stay up?
If only I could have gotten the Glen Garry leads. I could have been somebody...
Once again...
Two posters claim they are not are not long or short yet post incessantly on every movement. One says it is a sham (uses the word over and over), so here's a thought---become a whistleblower. I'm sure DARPA, universities, the CDC, top researchers, Time magazine and the country of India would benefit from your keen insight. The other says nothing will happen for 3 years yet posts 10 times as often as anyone who is invested.
Ask yourself why. And ask yourself why they'd do it unless there was a financial incentive to do so. Got to do something between the telemarketing calls for timeshare units, huh?
nothing happens but we will post all the time. Think about it.
I think you are correct. It is hard to know given I can't figure out how early any licensing deals can occur. Still buying along the way.
Not sure yet about the loans and them building their own facility seems high cost. Anyone know if licensing is one time or is any given user paying each year as they use the technology. I assume two officers have great ties overseas.
I honestly don't know. I am not implying that. The blood markers are interesting but not proof Aethlon's product is in use. I'd like to believe there is some news before the shareholder meeting. But until they state it, it is not so. I'd like to believe the Accesswire press release that mentioned Lilly got it wrong and it's really something with Abbott. However it may certainly be the case that Accesswire was flat wrong and there is nothing with Abbott. The good news regardless is that blood markers are viable as a method for learning more.
If you go to www.startribune.com, you will find a big, front page story on this from a few days ago. No reply from anyone on the email sent. Mildly surprised Mayo is not involved but my alma mater shares with them so maybe they'll get involved.
Is anyone sure what the agenda is at the shareholder meeting? I may go but not if its twenty minutes and done.
Concussion Study Biggest Yet
HCMC and Abbott Labs. Blood markers mentioned. ABT is the ticker. Info was sent to company and IR on Wednesday. I'd like to think they already knew but who knows. Starting with 9000 subjects
The avenues for revenue are as follows.
The technology as tool for other companies with their own product development. We supposedly have someone on board to sell that concept to other companies now. This was discussed for years and long overdue in my opinion. Does not need FDA approval. Potential in income has not been disclosed to my knowledge.
Sepsis may or may NOT be finished by September. US govt could pass or ask for additional tests. Mr. Joyce was clear that guidance won't be given since it's the governments project. It'd be nice to expect it but there's no sense of why one would at this moment.
Things like Zika or Ebola are not clear. Do safety trials have to progress before any quantity of significance can be distributed? I don't know but if I can attend the meeting I will ask.
Cash from isolating a product and selling part of the ownership such as the CTE application. Income but not revenue of course. Most of us wonder why that can't happen to drive up the market cap and improve the enterprise value. Perhaps that will occur after safety trials.
India and medical tourism was dangled by some but in hindsight Aethlon was unable to produce the HP in quantity and also indicated they didn't want to mess up US trials At least the then IR people told me that. It appears getting a Nasdaq listing curtails such musings since India as a revenue source has disappeared.
The poster you responded to has stated the company has done nothing and will do nothing for a couple of years yet posts as often as anyone. A poster on yahoo posts incessently against the company but believes an Ebola apron company is a great investment because newer investors after him are idiots. If you are sincere yourself then ask why they bother.
I believe newer shareholders of size will demand or possibly help the process. This company I believe will succeed or fail within two years. Opinion only. The shareholder meeting better have news and I think if the company has value it cannot go it alone by two or so years. Lots of ifs but Matthew Finston and that ilk have bashed while leaving many things out
You are absolutely correct. I don't like it either but there is no alternative.
They have to achieve more progress with US testing and that costs money. If Aemd is worth much more then valuation has to drive further by the company's progress before someone could buy it. That's "if".
For the Lilly reference see January 5th Accesswire release. Not from the company. If true it's great. If not, how on earth did such a false statement get published?
Truly there are impressive points with the company. Never did I imagine it could take so long.
I really don't mind negative posts but
I do not understand Hopester. Analyzes technicals for days and then says the company is not worth investing in. I can't imagine spending so much time on a stock you won't touch. Hmmm
Efficacy tests indeed must have NO more delays. None of us understand whether efficacy trials are needed before any deal is possible or further compassionate use could be considered. But the false start with the prior lead researcher is one more setback.
The Lilly mention by Accesswire must be clarified or refuted. The IR contact a few weeks ago would neither confirm nor deny. Who else has spoken to them? What are the rules on something seemingly so material (or a bad rumor printed by a third party seemingly as fact)? At what point is the company obligated to clarify?
What have the newer large holders been told? It has to be more than the vague plans we've seen to this point.
India. Never explained why Hep C didn't take hold, acknowledged it wasn't the right path in hindsight but back we are for dengue. Is the HP really good on a mass basis? If so why not Hep C?
Sepsis is now going to be a complete surprise. More tests after September? No reason the Feds couldn't extend more. He was clear on the call we'll not be getting public guidance.
It may drop on Monday. But either you believe holiday sales are good, meaning nice retailers will be announced or you shouldn't invest. If they don't make a nice run of holiday numbers listing anywhere won't realy matter. The overall share count is still low. Yes dilution always matters but twenty some million shares is still good
Small position in MCW Energy.
Anybody have a serious sense of what happens with dilution of the stock? Could licensing alleviate but not eliminate the need for issuance of new shares?
Technology makes sense but like other situations, a rush of new shares offsets any gains in advancement.
Thanks in advance. I've not talked with investor relations yet. Has anybody?
I want progress for concussions as well. However, google Dr. Robert Stern and the Minneapolis Star Tribune to get an idea of the timeline.
We need news on the safety trials for Hep C. This is getting beyond tiring.
Comparing notes
Curious who else has spoken with the newest IR firm. Long-time holder. My sense is the following:
1) Very disappointed that the tools to sell to other companies for their own development of drug trials was unfamiliar to the IR firm. I assume this is dead and that's a major disappointment given it was supposedly the fastest path to revenue
2) Didn't ask them about MD Anderson but whatever happened to that?
3) I passed on any discussion on dengue fever despite their efforts. I'm tired of hearing about it and cannot fathom at the moment why if dengue has not been viable so far as a treatable (commercially speaking) product why the newest Chukaya...something fever would be. Seems like the same scenario in that I can't figure for the life of me who pays for it if a government wouldn't?
4) Hep C. Have not gotten a definitive answer on why it's viable in the US but not viable in India. If the concern is something could go wrong in India that could affect US trials then why did we start there at all? I was told a few years ago that yes, they should have tried Europe first but viability has been proven and nothing. Yet the IR firm featured this to me along with cancer
5) Cancer: yes lots of promise but what funds it?
6) Concussions: Sorry to say but an interview Dr. Stern gave earlier this year to my local paper explains a viable test is years off. And, no one is funding it.
7) Is the real value in sepsis that it moves to human trials/can work as an indicator for value with other diseases
Lastly, the safety trials for Hep C are India-like in their slowness. The biggest mistake I've made was thinking that since it dialysis like, it would go more quickly than it has either overseas or here. Really wrong on that.
Would Like to Compare a Few Thoughts Here
1) Was given the impression last year by the IR person that IP would hopefully be straightened out with outside entities so the first money-maker, tests to OTHER cancer developers could start. Was always assuming that was the first stream of revenue. Was told in June, perhaps by the end of last year.
2) MD Anderson; yes, it is a long-term distribution of money but where is that going?
3) A competiors, Exosome Diagnostics, has perhaps had 25 million invested, seeking about the same again if I undestood things right. This gives an implied valuation of probably over $100 million, assuming those monies didn't/won't buy 100% of the company. ESI is internally valued at $7 million if you remember right. Why can't the funding go through ESI and limit some of the dilution
4) I've looked the CEO in the eye and told him several years ago that dilution was a concern with the go-it-alone strategy. He agreed, I believe he believes that too BUT the vision is cloudier to us retail investors than 5 years ago, at least in my opinion. And dilution MORE of a concern
5) Hep C and HIV need more clarification if AEMDD is going to be an adjunct therapy.
6) Just who is the IR representative now? I don't need to contact Mr. Joyce if there is now someone else but I don't see the names of the IR people in recent press releases. Any thoughts from anyone?
7) Concussion funding---I don't see that the NFL has put money anywhere. Did the players settlement need to be finalized first? Have others gotten money?
Thanks in advance.